Jefferson Bridge Capital LLC Makes New Investment in Pfizer Inc. $PFE

Jefferson Bridge Capital LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 53,410 shares of the biopharmaceutical company’s stock, valued at approximately $1,330,000. Pfizer accounts for about 1.3% of Jefferson Bridge Capital LLC’s investment portfolio, making the stock its 28th biggest position.

A number of other large investors have also recently made changes to their positions in the stock. Mattern Wealth Management LLC boosted its stake in shares of Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares during the period. Peak Asset Management LLC boosted its stake in shares of Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after purchasing an additional 402 shares during the period. Quest Investment Management LLC boosted its stake in shares of Pfizer by 1.3% during the third quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock valued at $809,000 after purchasing an additional 405 shares during the period. Community Bank & Trust Waco Texas boosted its stake in shares of Pfizer by 0.6% during the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after purchasing an additional 412 shares during the period. Finally, CVA Family Office LLC boosted its stake in shares of Pfizer by 3.3% during the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after purchasing an additional 413 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PFE. TD Cowen reissued a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research note on Monday, March 2nd. Guggenheim boosted their target price on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Barclays began coverage on Pfizer in a report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. Finally, Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.19.

Pfizer Stock Performance

PFE stock opened at $27.10 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The business has a 50-day moving average price of $27.14 and a 200 day moving average price of $25.89. The company has a market capitalization of $154.07 billion, a P/E ratio of 19.92 and a beta of 0.43. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.63 earnings per share. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer filed a new Phase 1 study (PF-07328948), signaling continued pipeline investment and R&D momentum that supports longer-term growth prospects. Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
• Positive Sentiment: Optimistic retail/analyst takes: at least one bullish piece argues PFE looks undervalued and could be a strong buy over a multi-year horizon, which can support investor appetite for the stock on dips. Prediction: In 5 Years, You’ll Wish You Bought Pfizer Stock Today
• Neutral Sentiment: Market correlation: some coverage notes today’s action is tied to broader S&P 500 moves rather than company-specific news, which can amplify price swings independent of fundamentals. Pfizer Inc. Market Action Tied To S&P 500 Index Movement
• Neutral Sentiment: Feature pieces weigh reasons to watch PFE while advising caution — helpful context for investors assessing valuation versus near-term risks. 2 Reasons to Watch PFE and 1 to Stay Cautious
• Neutral Sentiment: Sector competitive landscape: coverage of the expanding “diabesity” (GLP‑1) market highlights big opportunities for peers like Lilly and Novo Nordisk — an indirect signal that competition and missed participation in the category could pressure Pfizer’s long‑term growth narrative. The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts.
• Negative Sentiment: Clinical setback: Pfizer and its COVID‑19 vaccine partner paused an updated‑shot trial, which prompted immediate selling pressure and raises short‑term uncertainty about their COVID franchise strategy. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Policy risk: reports that a Washington proposal could impose steep tariffs (or a 100% framework) on drugmakers without pricing agreements added regulatory and political risk that can pressure valuations in the near term. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Market reaction note: headline summaries show the stock has moved lower amid these combined factors, which explains today’s downward price action versus recent highs. Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.